Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

IVA

Inventiva (IVA)

Inventiva
Date:
Sort by:
 Showing the most relevant articles for your search:EU:IVA
DateTimeSourceHeadlineSymbolCompany
22/05/202406:00GlobeNewswire Inc.Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateEU:IVAInventiva
22/05/202406:00GlobeNewswire Inc.Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateEU:IVAInventiva
22/05/202406:00GlobeNewswire Inc.Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activitésEU:IVAInventiva
17/05/202406:00GlobeNewswire Inc.Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASHEU:IVAInventiva
17/05/202406:00GlobeNewswire Inc.Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHEU:IVAInventiva
13/05/202416:30GlobeNewswire Inc.Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorEU:IVAInventiva
13/05/202416:30GlobeNewswire Inc.Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorEU:IVAInventiva
13/05/202416:30GlobeNewswire Inc.Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traitéEU:IVAInventiva
04/04/202407:00GlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
04/04/202407:00GlobeNewswire Inc.Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)EU:IVAInventiva
04/04/202407:00GlobeNewswire Inc.Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FEU:IVAInventiva
28/03/202418:00GlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
28/03/202418:00GlobeNewswire Inc.Inventiva announces the nomination of Andre Turenne as DirectorEU:IVAInventiva
28/03/202418:00GlobeNewswire Inc.Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateurEU:IVAInventiva
28/03/202407:00GlobeNewswire Inc.Inventiva publie ses résultats annuels 2023EU:IVAInventiva
28/03/202407:00GlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
28/03/202407:00GlobeNewswire Inc.Inventiva reports its 2023 full-year resultsEU:IVAInventiva
23/03/202407:00GlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
23/03/202407:00GlobeNewswire Inc.Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023EU:IVAInventiva
23/03/202407:00GlobeNewswire Inc.Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsEU:IVAInventiva
19/03/202407:00GlobeNewswire Inc.Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2EU:IVAInventiva
19/03/202407:00GlobeNewswire Inc.Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
14/03/202407:00GlobeNewswire Inc.Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2EU:IVAInventiva
14/03/202407:00GlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
14/03/202407:00GlobeNewswire Inc.Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2DEU:IVAInventiva
08/03/202408:00GlobeNewswire Inc.Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedEU:IVAInventiva
08/03/202408:00GlobeNewswire Inc.Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedEU:IVAInventiva
08/03/202408:00GlobeNewswire Inc.Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH  EU:IVAInventiva
16/02/202408:35GlobeNewswire Inc.Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3EU:IVAInventiva
16/02/202408:35GlobeNewswire Inc.Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3EU:IVAInventiva
 Showing the most relevant articles for your search:EU:IVA

Your Recent History

Delayed Upgrade Clock